Valeant Pharmaceuticals International Downgraded by TD Securities to Hold (VRX)
Valeant Pharmaceuticals International (TSE:VRX) was downgraded by analysts at TD Securities from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Analyst Ratings Net reports. They currently have a C$135.00 target price on the stock. TD Securities’ target price points to a potential downside of 0.02% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at UBS AG raised their price target on shares of Valeant Pharmaceuticals International from C$115.00 to C$125.00 in a research note to investors on Tuesday, December 3rd. They now have a “buy” rating on the stock. Analysts at RBC Capital raised their price target on shares of Valeant Pharmaceuticals International from C$115.00 to C$117.00 in a research note to investors on Wednesday, October 23rd. They now have an “outperform” rating on the stock. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of C$139.80.
Valeant Pharmaceuticals International (TSE:VRX) traded up 2.67% on Wednesday, hitting $138.64. The stock had a trading volume of 781,022 shares. Valeant Pharmaceuticals International has a one year low of $61.58 and a one year high of $135.71. The stock has a 50-day moving average of $117.5 and a 200-day moving average of $107.. The company’s market cap is $46.290 billion.
Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.